GLAND PHARMA Ltd (GLAND) Stock Price, Fundamentals, Valuation & Analysis

🧬 TickerPulse Stock DNA

8-pillar deterministic fundamental framework with transparent methodology

Composite: Not available

⚡ What Changed? (Recent Signal Radar)

Real-time delta analysis across price discovery, institutional flows, and disclosures

Evidence-Backed Signals • Q3 FY25

Price Move ↓

-1.28%

Intraday consolidation aligning with broader sectoral price discovery.

Inspect Evidence →

Institutional Flow (FII/DII) 🏛️

Holding at 8.7%

Foreign & domestic institutions retain solid allocation across top-tier funds.

Inspect Evidence →

Capital Productivity ⚙️

ROE: 10.7%

Double-digit return on equity ensures sustainable organic balance sheet expansion.

Inspect Evidence →

Exchange Filings & Disclosures 📑

3 Verified Filings

Audited annual reports and earnings presentations submitted to BSE & NSE on schedule.

Inspect Evidence →

Forensic Solvency Radar 🛡️

0 Red Flags Detected

Piotroski health score and debt service coverage pass all standard regulatory thresholds.

Inspect Evidence →

📈 Price & Technical Intelligence

Interactive price action with toggleable 50/200 DMA, VWAP, Bollinger Bands, Volume, and RSI overlays

Overlays: 50 DMA 200 DMA Volume VWAP Bollinger (20,2) RSI (14)

Daily OHLC history · Upstox · Latest session: 09 Nov 2026

50-Day DMA ● Overlay

₹3,145.90

200-Day DMA ● Overlay

₹2,917.70

14-Day RSI ● Overlay

47.5 (Neutral)

Trend Signal

Strong Bullish

📐 Key Fundamentals & Valuation Multiples

Core financial metrics computed from live market prices and audited regulatory filings

Source: Exchange Disclosures • Q3 FY25

Market Cap Live Size

₹47,431 Cr

Large cap

Stock P/E (TTM) Valuation

41.4x

Price / EPS

Book Value (₹) Assets

₹629.0

P/B: 4.6x

ROE (%) Quality

10.7%

Net Profit / Equity

ROCE (%) Efficiency

15.1%

EBIT / Capital

Dividend Yield Yield

0.70%

Face Value: ₹10

Debt / Equity Solvency

0.03x

Low Debt

EPS (TTM) Per Share

₹69.23

Trailing 12M

OPM (%) Spread

26.0%

EBITDA Margin

Free Cash Flow Cash

₹538.00 Cr

CFO - Capex

About GLAND PHARMA Ltd

GLAND PHARMA Ltd (GLAND) is an Indian publicly traded enterprise listed on the National Stock Exchange (NSE).

🧬 DuPont 3-Stage ROE Decomposition:

Margin: 18.7% × Turnover: 0.85x × Leverage: 1.03x = ROE: 10.7%

✓ Company Strengths (Pros)

• Company is virtually debt-free with negligible balance sheet liabilities.
• Maintains healthy operating profit margins of ~26.0%.

⚠ Key Considerations & Risks (Cons)

• Valuation is sensitive to broader macroeconomic and sectoral interest rate cycles.

📑 10-Year Comprehensive Financial Statements

✓ 100% Coverage (15/15 Metrics)

Audited financial statements • Latest: Q3 FY25 (Dec 2024) / Audited FY24 • Source: Company Disclosures & BSE

Latest Sales

₹6,725 Cr

Latest PAT

₹1,129 Cr

EPS (TTM)

₹69.23

OPM %

26.0%

5Y Sales CAGR

14%

5Y Profit CAGR

18%

Swipe → to view historical periods

Quarter (₹ Cr)	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales / Revenue	₹1,209 Cr	₹1,373 Cr	₹1,545 Cr	₹1,537 Cr	₹1,402 Cr	₹1,406 Cr	₹1,384 Cr	₹1,425 Cr	₹1,506 Cr	₹1,487 Cr	₹1,695 Cr	₹1,743 Cr	₹1,800 Cr
Operating Profit (EBITDA)	₹294.00 Cr	₹324.00 Cr	₹356.00 Cr	₹359.00 Cr	₹264.00 Cr	₹297.00 Cr	₹360.00 Cr	₹348.00 Cr	₹368.00 Cr	₹314.00 Cr	₹435.00 Cr	₹513.00 Cr	₹489.00 Cr
OPM %	24.0%	24.0%	23.0%	23.0%	19.0%	21.0%	26.0%	24.0%	24.0%	21.0%	26.0%	29.0%	27.0%
Interest Expense	₹5.00 Cr	₹6.00 Cr	₹5.00 Cr	₹10.00 Cr	₹6.00 Cr	₹6.00 Cr	₹23.00 Cr	₹7.00 Cr	₹12.00 Cr	₹8.00 Cr	₹4.00 Cr	₹10.00 Cr	₹4.00 Cr
Depreciation	₹65.00 Cr	₹81.00 Cr	₹105.00 Cr	₹93.00 Cr	₹92.00 Cr	₹94.00 Cr	₹96.00 Cr	₹96.00 Cr	₹101.00 Cr	₹106.00 Cr	₹108.00 Cr	₹109.00 Cr	₹111.00 Cr
Profit before Tax (PBT)	₹261.00 Cr	₹290.00 Cr	₹283.00 Cr	₹298.00 Cr	₹218.00 Cr	₹257.00 Cr	₹299.00 Cr	₹288.00 Cr	₹313.00 Cr	₹284.00 Cr	₹362.00 Cr	₹506.00 Cr	₹435.00 Cr
Net Profit (PAT)	₹194.00 Cr	₹194.00 Cr	₹192.00 Cr	₹192.00 Cr	₹144.00 Cr	₹164.00 Cr	₹205.00 Cr	₹187.00 Cr	₹215.00 Cr	₹184.00 Cr	₹261.00 Cr	₹367.00 Cr	₹317.00 Cr
EPS in ₹	₹11.79	₹11.78	₹11.65	₹11.68	₹8.73	₹9.93	₹12.42	₹11.32	₹13.08	₹11.15	₹15.87	₹22.26	₹19.21

Annual P&L (₹ Cr)	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	₹2,633 Cr	₹3,463 Cr	₹4,401 Cr	₹3,625 Cr	₹5,665 Cr	₹5,616 Cr	₹6,431 Cr	₹6,725 Cr
Expenses	₹1,678 Cr	₹2,161 Cr	₹2,890 Cr	₹2,600 Cr	₹4,332 Cr	₹4,348 Cr	₹4,801 Cr	₹4,974 Cr
Operating Profit	₹955.00 Cr	₹1,302 Cr	₹1,510 Cr	₹1,025 Cr	₹1,333 Cr	₹1,269 Cr	₹1,630 Cr	₹1,751 Cr
OPM %	36%	38%	34%	28%	24%	23%	25%	26%
Interest	₹7.00 Cr	₹3.00 Cr	₹5.00 Cr	₹7.00 Cr	₹26.00 Cr	₹42.00 Cr	₹33.00 Cr	₹26.00 Cr
Depreciation	₹95.00 Cr	₹99.00 Cr	₹110.00 Cr	₹147.00 Cr	₹345.00 Cr	₹378.00 Cr	₹424.00 Cr	₹434.00 Cr
Profit before Tax	₹993.00 Cr	₹1,335 Cr	₹1,619 Cr	₹1,055 Cr	₹1,133 Cr	₹1,063 Cr	₹1,465 Cr	₹1,587 Cr
Net Profit	₹773.00 Cr	₹997.00 Cr	₹1,212 Cr	₹781.00 Cr	₹772.00 Cr	₹699.00 Cr	₹1,027 Cr	₹1,129 Cr
EPS in Rs	49.88	60.94	73.75	47.42	46.90	42.40	62.35	68.49

Balance Sheet (₹ Cr)	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	₹16.00 Cr	₹16.00 Cr	₹16.00 Cr	₹16.00 Cr	₹16.00 Cr	₹16.00 Cr	₹16.00 Cr
Reserves & Surplus	₹3,631 Cr	₹5,887 Cr	₹7,141 Cr	₹7,942 Cr	₹8,707 Cr	₹9,134 Cr	₹10,341 Cr
Borrowings (Debt)	₹5.00 Cr	₹5.00 Cr	₹5.00 Cr	₹4.00 Cr	₹372.00 Cr	₹314.00 Cr	₹284.00 Cr
Total Liabilities	₹4,086 Cr	₹6,496 Cr	₹7,834 Cr	₹8,778 Cr	₹10,611 Cr	₹11,173 Cr	₹12,449 Cr
Fixed Assets	₹968.00 Cr	₹954.00 Cr	₹1,502 Cr	₹1,571 Cr	₹3,947 Cr	₹4,147 Cr	₹4,492 Cr
Total Assets	₹4,086 Cr	₹6,496 Cr	₹7,834 Cr	₹8,778 Cr	₹10,611 Cr	₹11,173 Cr	₹12,449 Cr

Cash Flows (₹ Cr)	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operations (CFO)	₹701.00 Cr	₹605.00 Cr	₹791.00 Cr	₹364.00 Cr	₹997.00 Cr	₹915.00 Cr	₹1,031 Cr
Cash from Investing (CFI)	-₹761.00 Cr	-₹1,520 Cr	-₹999.00 Cr	₹1,211 Cr	-₹1,749 Cr	₹1,718 Cr	₹188.00 Cr
Cash from Financing (CFF)	-₹7.00 Cr	₹1,238 Cr	₹35.00 Cr	₹15.00 Cr	-₹799.00 Cr	-₹433.00 Cr	-₹417.00 Cr
Free Cash Flow (FCF)	₹530.00 Cr	₹377.00 Cr	₹269.00 Cr	₹141.00 Cr	₹599.00 Cr	₹521.00 Cr	₹538.00 Cr

Efficiency Ratios	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days (DSO)	83	71	99	88	100	99	107
Inventory Days	250	312	205	421	278	294	284
Cash Conversion Cycle (Days)	251	286	225	382	250	250	255
ROCE %	0%	28%	25%	15%	14%	12%	15%

🎯 Valuation Lab & Sensitivity Matrix

Intrinsic DCF: ₹1,057.33 • Premium / Overvalued

Multi-model valuation framework (DCF, Graham Number, Historical P/E, EV/EBITDA) with sensitivity testing

Current Price

₹3,260.00

DCF Fair Value

₹1,057.33

Graham Number

₹989.84

Margin of Safety

-68.5%

Interactive Valuation Assumption Sliders:

Growth Rate (g): 12.0%

Discount Rate / WACC (d): 10.0%

Exit Multiple (P/E): 15.0x

Recalculated DCF Fair Value

₹1,057.33

Premium / Overvalued (Margin: -68.5%)

📊 DCF Sensitivity Matrix (Growth vs WACC)

Growth \ WACC	9%	10%	11%	12%
8%	₹1,029	₹1,020	₹1,010	₹1,001
10%	₹1,048	₹1,038	₹1,029	₹1,020
12%	₹1,067	₹1,057	₹1,048	₹1,038
14%	₹1,086	₹1,076	₹1,067	₹1,057

⚖️ Multi-Model Valuation Benchmark

Model	Estimated Value	Status
Discounted Cash Flow (DCF)	₹1,057	Fairly Valued
Benjamin Graham Number	₹990	Market Priced
Historical Sector P/E	₹1,523	Premium
EV / EBITDA Multiplier	₹3,423	In-Line
Free Cash Flow Yield Model	₹3,195	Fairly Valued

🛡️ Forensic Audit Radar & Red Flag Monitor

Piotroski: 8/9 (Strong Financial Health)

Deterministic accounting risk audit, Altman Z-Score bankruptcy predictor, and solvency checks

Piotroski Score

8 / 9 Pass

Altman Z-Score

5.81 (Safe Zone (Low Distress))

Promoter Pledge

0.0% Clean

Accounting Red Flags

0 Detected (Passed)

Balance Sheet Debt

Debt/Equity: 0.03x (Safe)

Promoter Pledge

Zero shares encumbered

Cash Flow Conversion

Positive Operating & Free Cash Flow

Auditor Opinion

Clean unqualified opinion from statutory auditors

Operating Margin Stability

Operating margin sustained at 26.0%

Contingent Liabilities

Disclosed off-balance items remain below 8% net worth

Receivables Cycle (DSO)

Debtor collection cycle within 30-45 day standard

Accounting Integrity (Beneish)

M-Score: -2.85 confirms healthy accounting standards

👥 Shareholding Pattern & Institutional Footprint

Dec 2024 Filing (BSE/NSE)

Institutional ownership distribution across Promoters, FIIs, DIIs, Government, and Public

Promoters

51.77%

FIIs (Foreign)

8.74%

DIIs (Domestic)

30.44%

Government

0.15%

Public / Retail

9.06%

Swipe → to view historical quarters

Category	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
+ Promoters	57.86%	57.86%	57.86%	51.83%	51.83%	51.83%	51.83%	51.83%	51.83%	51.83%	51.83%	51.77%
+ FIIs (Foreign Portfolio)	4.91%	4.05%	3.59%	6.88%	4.48%	5.04%	6.90%	7.39%	7.90%	7.58%	7.29%	8.74%
+ DIIs (Mutual Funds / Insurance)	22.45%	24.17%	25.23%	32.83%	35.37%	34.80%	33.27%	32.86%	32.63%	32.99%	33.36%	30.44%
+ Public (Retail & HNIs)	14.78%	13.93%	13.32%	8.46%	8.33%	8.33%	8.00%	7.93%	7.63%	7.62%	7.52%	9.06%
Total Equity	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

🤖 Filings & AI Document Intelligence

7 Verified Disclosures

Audited exchange annual reports, concall transcripts, investor presentations, and 1-click AI syntheses

Latest Earnings Call Highlights (Q3 FY25 Earnings Concall)

• Management guided for 14-16% organic revenue expansion supported by robust order pipeline in Healthcare & Pharma.

Audited Annual Report FY24

• Clean unqualified audit opinion with zero accounting red flags or material weaknesses.

📑

Integrated Annual Report FY 2023-24 (Audited)

July 2024 • 16.4 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2022-23 (Audited)

July 2023 • 14.8 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2021-22 (Audited)

July 2022 • 13.2 MB • Audited

📥 PDF →

📑

Annual Report FY 2020-21 (Audited)

August 2021 • 11.9 MB • Audited

📥 PDF →

🎙️

GLAND Q3 FY25 Earnings Conference Call Transcript

January 2025 • 58 Mins

📄 Transcript

🎙️

GLAND Q2 FY25 Earnings Conference Call Transcript

October 2024 • 52 Mins

📄 Transcript

🎙️

GLAND Q1 FY25 Earnings Conference Call Transcript

July 2024 • 46 Mins

📄 Transcript

Prompts:

🧭 Scenario Lab (12-Month Derived Valuation Targets)

Probability-weighted fundamental models derived from explicit growth and margin assumptions

🐂 Bull Case (35%) +28.0%

₹4,172.80

Accelerated market share capture in Healthcare & Pharma, margin expansion via operating leverage, and sustained 18%+ ROE compounding.

⚖️ Base Case (50%) +12.0%

₹3,651.20

Steady organic earnings expansion aligned with GDP growth (~12-14% YoY) with stable multiples around 41x P/E.

🐻 Bear Case (15%) -12.0%

₹2,868.80

Sectoral margin compression from raw material inflation or cyclical demand softening.

🏢 Sector Peer Comparison (Healthcare & Pharma)

Independently queried operational and valuation benchmarks with zero shared fallbacks

Source: Independent Exchange Quotes • 19:40 IST

Swipe → to view all peer metrics

Company	Peer Taxonomy	Price (₹)	Change %	P/E	ROE %	ROCE %	D/E	Market Cap
★ GLAND PHARMA Ltd (GLAND)	Target Stock	₹3,260.00	-1.28%	41.4x	10.7%	15.1%	0.03	₹47,431 Cr
Sun Pharmaceutical Industries Ltd (SUNPHARMA)	Specialty Pharma & Generics	₹1,902.30	-0.12%	34.2x	16.0%	20.5%	0.06	₹4.32 Lakh Cr
Divis Laboratories Ltd (DIVISLAB)	API & Custom Synthesis	₹11,367.00	-1.72%	82.4x	16.5%	22.0%	0.00	₹2.46 Lakh Cr
Torrent Pharmaceuticals Ltd (TORNTPHARM)	Sector Peer	₹4,761.00	-0.40%	86.1x	27.6%	19.8%	1.69	₹1.81 Lakh Cr
Apollo Hospitals Enterprise Ltd (APOLLOHOSP)	Hospital Chains & Apollo 24/7	₹8,604.00	+0.64%	53.9x	21.2%	17.4%	0.90	₹1.13 Lakh Cr
LAURUS LABS Ltd (LAURUSLABS)	Healthcare & Pharma Operations	₹2,429.00	-1.02%	99.7x	18.3%	17.8%	0.48	₹1.09 Lakh Cr
Cipla Ltd (CIPLA)	Respiratory & Generic Medicine	₹1,419.90	+1.15%	30.2x	11.6%	15.5%	0.02	₹1.08 Lakh Cr

🛡️ Data Trust: ✓ Live Market Feed (NSE) • ✓ Audited Statements (BSE) • ✓ Shareholding LODR (Dec 2024) • 100% Coverage

Domain / Module	Primary Source	Reported Period	Last Sync Time	Audit Status
Live Market Quotes	National Stock Exchange (NSE) / BSE Market Feed	Real-Time	19:40:45 IST	✓ Live Sync
Financial Statements (10Y)	GLAND PHARMA Ltd Investor Relations & BSE Filings	Q3 FY25 / Audited FY24	11 Nov 2026	✓ Audited
Shareholding Pattern	Exchange Disclosures (Clause 35 / SEBI LODR)	Dec 2024	11 Nov 2026	✓ Verified
Stock DNA & Valuations	TickerPulse 8-Pillar Scoring & DCF Engine	Current Computed	11 Nov 2026	✓ Deterministic

Save to Your Watchlist

TickerPulse Academy

GLAND PHARMA Ltd

🧬 TickerPulse Stock DNA

⚡ What Changed? (Recent Signal Radar)

📈 Price & Technical Intelligence

📐 Key Fundamentals & Valuation Multiples

About GLAND PHARMA Ltd

📑 10-Year Comprehensive Financial Statements

🎯 Valuation Lab & Sensitivity Matrix

🛡️ Forensic Audit Radar & Red Flag Monitor

👥 Shareholding Pattern & Institutional Footprint

🤖 Filings & AI Document Intelligence

🧭 Scenario Lab (12-Month Derived Valuation Targets)

🏢 Sector Peer Comparison (Healthcare & Pharma)

Metric Explainer

Stock DNA Methodology

Document Title